Back

Therapeutic voyage of synthetic and natural xanthine oxidase inhibitors.

  • Published In: Chemical Biology & Drug Design, 2023, v. 102, n. 5. P. 1293 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Agrawal, Neetu; Arya, Medha; Kushwah, Priya 3 of 3

Abstract

Xanthine oxidase (XO) inhibitors are commonly used to treat gout, nephropathy, and renal stone diseases related to hyperuricemia. However, recent research has shown that these inhibitors may also have potential benefits in preventing vascular diseases, including those affecting the cerebrovasculature. This is due to emerging evidence suggesting that serum uric acid is involved in the growth of cardiovascular disease, and XO inhibition can reduce oxidative stress in the vasculature. There is a great interest in the development of new XO inhibitors for the treatment of hyperuricemia and gout. The present review discusses the many synthetic and natural XO inhibitors that have been developed which are found to have greater potency. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Chemical Biology & Drug Design. 2023/11, Vol. 102, Issue 5, p1293
  • Document Type:Article
  • Subject Area:Complementary and Alternative Medicine
  • Publication Date:2023
  • ISSN:1747-0277
  • DOI:10.1111/cbdd.14319
  • Accession Number:172959899
  • Copyright Statement:Copyright of Chemical Biology & Drug Design is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.